Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly

被引:131
作者
Stomrud, Erik [1 ]
Hansson, Oskar
Blennow, Kaj
Minthon, Lennart
Londos, Elisabet
机构
[1] Lund Univ, Malmo Univ Hosp, Dept Clin Sci Malmo, Clin Memory Res Unit, SE-20502 Malmo, Sweden
[2] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Molndal, Sweden
关键词
Alzheimer disease; early diagnosis; dementia; mild cognitive impairment; cerebrospinal fluid biomarker; Tau protein; beta-amyloid; 42;
D O I
10.1159/000105017
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective: To investigate whether cerebrospinal fluid (CSF) biomarkers can predict cognitive decline in healthy, elderly individuals as they have been shown to do in cognitively impaired patient samples. Methods: In this study, 57 controls were tested for CSF biomarkers at baseline and then cognitively followed over 3 years. Results: Low levels of baseline beta-amyloid 1 - 42 (A beta 42) were associated with development of subjective memory impairment affecting quality of life (memQoL), with a worse Mini Mental Status Examination score and with inability to live in regular housing at follow-up ( p < 0.05). The combination of baseline A beta 42 and phosphorylated tau (P-tau) was found to predict development of pathological memQoL with a sensitivity of 71.4% and a specificity of 75.7 (< 0.01). Conclusion: Low A beta 42 and combined A beta 42 and P-tau predicted subjective cognitive decline in healthy individuals. In summary, this study shows that already in the clinically normal population Alzheimer-disease-related biological signs might be detectable. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:118 / 124
页数:7
相关论文
共 37 条
[1]  
Almkvist O, 1999, EUR ARCH PSY CLIN N, V249, P3
[2]   CSF biomarkers for mild cognitive impairment and early Alzheimer's disease [J].
Andreasen, N ;
Blennow, K .
CLINICAL NEUROLOGY AND NEUROSURGERY, 2005, 107 (03) :165-173
[3]   Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice [J].
Andreasen, N ;
Minthon, L ;
Davidsson, P ;
Vanmechelen, E ;
Vanderstichele, H ;
Winblad, B ;
Blennow, K .
ARCHIVES OF NEUROLOGY, 2001, 58 (03) :373-379
[4]   CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia [J].
Bibl, M ;
Mollenhauer, B ;
Esselmann, H ;
Lewczuk, P ;
Klafki, HW ;
Sparbier, K ;
Smirnov, A ;
Cepek, L ;
Trenkwalder, C ;
Rüther, E ;
Kornhuber, J ;
Otto, M ;
Wiltfang, J .
BRAIN, 2006, 129 :1177-1187
[5]   Alzheimer's disease [J].
Blennow, Kaj ;
de Leon, Mony J. ;
Zetterberg, Henrik .
LANCET, 2006, 368 (9533) :387-403
[6]   Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment [J].
de Leon, MJ ;
DeSanti, S ;
Zinkowski, R ;
Mehta, PD ;
Pratico, D ;
Segal, S ;
Rusinek, H ;
Li, J ;
Tsui, W ;
Saint Louis, LA ;
Clark, CM ;
Tarshish, C ;
Li, Y ;
Lair, L ;
Javier, E ;
Rich, K ;
Lesbre, P ;
Mosconi, L ;
Reisberg, B ;
Sadowski, M ;
DeBernadis, JF ;
Kerkman, DJ ;
Harnpel, H ;
Wahlund, LO ;
Davies, P .
NEUROBIOLOGY OF AGING, 2006, 27 (03) :394-401
[7]  
DORN H F, 1955, J Chronic Dis, V1, P638, DOI 10.1016/0021-9681(55)90221-6
[8]   Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults [J].
Fagan, Anne M. ;
Roe, Catherine M. ;
Xiong, Chengjie ;
Mintun, Mark A. ;
Morris, John C. ;
Holtzman, David M. .
ARCHIVES OF NEUROLOGY, 2007, 64 (03) :343-349
[9]   MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].
FOLSTEIN, MF ;
FOLSTEIN, SE ;
MCHUGH, PR .
JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198
[10]  
Fratiglioni L, 2000, NEUROLOGY, V54, pS10